Advertisement
Advertisement
U.S. markets open in 4 hours 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Diffusion Pharmaceuticals Inc. (DFFN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2905+0.0186 (+6.84%)
At close: 04:00PM EST
0.2983 +0.01 (+2.69%)
Pre-Market: 04:00AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2719
Open0.2797
Bid0.0000 x 1800
Ask0.0000 x 2900
Day's Range0.2760 - 0.2954
52 Week Range0.2700 - 1.8500
Volume441,181
Avg. Volume1,373,448
Market Cap29.608M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-0.2730
Earnings DateMar 15, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DFFN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Diffusion Pharmaceuticals Inc.
    Daily – Vickers Top Buyers & Sellers for 01/11/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

    CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conferen

  • GlobeNewswire

    Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

    Third of Three TSC Oxygenation TrialsCHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has dosed the first patients in its ILD-DLCO Trial. The trial will evaluate the Company’s lead product candidate, trans sodium crocetinate (“TSC”), in patients with previo

  • GlobeNewswire

    Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

    Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of CancerCHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it has been granted United States Patent No. 11,185,523, “Use of Bipolar Trans Carotenoids With Chemotherapy and Radiot

Advertisement
Advertisement